Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067

This study is the first-in-human of ASKC202, which is an open-label, non-randomized, multicenter study with a dose escalation phase and a dose expansion phase.

Participants needed: 150
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Jiangsu Aosaikang Pharmaceutical Co., Ltd.Updated: Dec 23, 2025Locations: 3
Eligibility criteria

Willing and able to provide signed and dated informed consent; [+2]

Have previously received or are receiving any treatment for c-Mets (including al... [+17]

Read more
Status: Not yet recruiting

ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy

This study is designed to compare the safety and efficacy of ASKC202 combined with Limertinib Versus platinum-based chemotherapy in locally advanced or metastatic NSCLC With MET Amplification/Overexpression after disease progression on EGFR tyrosine kinase inhibitor.

Participants needed: 286
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Jiangsu Aosaikang Pharmaceutical Co., Ltd.Updated: Aug 7, 2025Locations: 1
Eligibility criteria

Willing and able to provide signed and dated informed consent; [+8]

Prior or ongoing treatment with any c-Met target; [+12]

Read more
Status: Not yet recruiting

The Safety and Pharmacokinetics of ASKC200 in Osteoarthritic Knee Pain

This is a multi-center, randomized, double-blind clinical trial to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ASKC200 in subjects with OA of the knees and determine the phase II recommended dose. Assigned doses will be applied for 60 minutes on each of four consecutive days.

Participants needed: 24
Trial details
Phase: Phase 1Age: 40-75Biological sex: AllType: InterventionalSponsor: Jiangsu Aosaikang Pharmaceutical Co., Ltd.Updated: Sep 27, 2024Locations: 1
Eligibility criteria

Sign informed consent prior to any inspection and evaluation, and understand and... [+7]

Secondary arthritis caused by other causes; [+10]

Read more